• Increased revenue and market share obtained through flexible and fast responses to market opportunities;
• Integration and alignment of internal processes which will lead to increased productivity and results;
• Enhanced business performance and better cost management;
• Providing confidence to interested parties as to the consistency, effectiveness and efficiency of the organisation;
• Increased credibility and competitiveness in the market;
Ad Statistics
Times Displayed: 51717
Times Visited: 1518 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
• Consistency in the delivery of clinical services;
• Lower costs and shorter cycle times through effective use of resources;
• Improved communication, planning and administration processes.
Proton Partners receipt of the prestigious certificate follows closely behind the news that work has now commenced on Proton Partners’ Northumberland site. The centre, situated at the Earth Balance wellness site in Bomarsund will be the second to be built by Proton Partners International in the UK and is expected to be operational by February 2018.
About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.
Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed non-executive chairman and Professor Karol Sikora is chief medical adviser to the company.
The Welsh Government’s Life Sciences Investment Fund is a key investor in Proton Partners International.
About Proton Beam Therapy
Proton beam therapy is a highly-targeted type of radiotherapy that can treat hard-to-reach cancers, such as spinal tumours (chordomas), with a lower risk of damaging the surrounding tissue and causing side effects.
Back to HCB News
